By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Pearl Therapeutics 

200 Saginaw Drive

Redwood City  California  94063  U.S.A.
Phone: 650-305-2600 Fax: 650-568-1804


Medical Device

Start Up

Company News
AstraZeneca PLC (AZN) in Deal for Pearl Therapeutics Worth Up to $1.15 Billion 6/10/2013 7:21:23 AM
Pearl Therapeutics Presents Dose-Ranging, Efficacy and Safety Results of PT003 as well as Components, PT001 and PT005 at American Thoracic Society Meeting 5/17/2013 9:10:22 AM
Pearl Therapeutics Initiates PT003 Phase 3 Program for the Treatment of Individuals with Moderate-to-Severe COPD 5/14/2013 9:42:12 AM
Pearl Therapeutics Receives Award for Innovative Co-Suspension Technology 3/14/2013 11:05:16 AM
Pearl Therapeutics Strengthens its Organization by Hiring Dr. Michael Riebe, an Industry Veteran in Respiratory Product Development 1/17/2013 9:09:19 AM
Pearl Therapeutics to Present at J.P. Morgan Healthcare Conference 1/4/2013 9:47:41 AM
Pearl Therapeutics Successfully Completes Phase 2 Program; Identifies Optimal Dose of PT003 and Its Components for Phase 3 10/24/2012 10:27:10 AM
Pearl Therapeutics Completes Phase 2b Study of Glycopyrrolate, Defines Dose-Response Curve and Identifies Optimal Dose of PT001 9/13/2012 9:52:09 AM
Pearl Therapeutics Receives TiE50 Award from Global Entrepreneurship Network 5/21/2012 12:11:14 PM
Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD 5/14/2012 10:44:47 AM